Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 27287207)

  • 1. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.
    Trillsch F; Mahner S; Czogalla B; Rottmann M; Chekerov R; Braicu EI; Oskay-Öczelik G; Wimberger P; Richter R; Sehouli J
    J Gynecol Oncol; 2021 May; 32(3):e37. PubMed ID: 33825355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
    Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    Lee CK; Asher R; Friedlander M; Gebski V; Gonzalez-Martin A; Lortholary A; Lesoin A; Kurzeder C; Largillier R; Hilpert F; Hardy-Bessard AC; Kaminsky MC; Poveda A; Pujade-Lauraine E
    Eur J Cancer; 2019 Aug; 117():99-106. PubMed ID: 31279306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
    Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
    Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; de Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E
    J Clin Oncol; 2014 May; 32(13):1309-16. PubMed ID: 24687829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Bamias A; Gibbs E; Khoon Lee C; Davies L; Dimopoulos M; Zagouri F; Veillard AS; Kosse J; Santaballa A; Mirza MR; Tabaro G; Vergote I; Bloemendal H; Lykka M; Floquet A; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2017 Aug; 28(8):1842-1848. PubMed ID: 28481967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
    Chikazawa K; Netsu S; Kuwata T; Konno R
    Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
    Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Moffat GT; Kong W; MacKay HJ; McGee J; Booth CM; Ethier JL
    Gynecol Oncol; 2024 May; 184():51-56. PubMed ID: 38281412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
    Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
    Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
    Kurzeder C; Bover I; Marmé F; Rau J; Pautier P; Colombo N; Lorusso D; Ottevanger P; Bjurberg M; Marth C; Barretina-Ginesta P; Vergote I; Floquet A; Del Campo JM; Mahner S; Bastière-Truchot L; Martin N; Oestergaard MZ; Kiermaier A; Schade-Brittinger C; Polleis S; du Bois A; Gonzalez-Martin A
    J Clin Oncol; 2016 Jul; 34(21):2516-25. PubMed ID: 27269942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
    Liu B; An R; Yu J
    J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.